Specifically the identification of a PAD4 inhibitor, produced naturally in the human body, as well as the prevention of ROS production might strongly improve the treatment of diseases associated with excessive NET formation, such as rheumatoid arthritis [67], multiple sclerosis [65], sepsis [17], heart failure, and myocardial infarction [66]. The gene discussed is PADI4; the disease is multiple sclerosis.